Catalyst
Slingshot members are tracking this event:
Novo Nordisk (NVO) Submits Type 2 Variation Application to EMA to Add Data from Two Late-Stage Studies to Label for Long-Acting Diabetes Med Tresiba
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Type 2 Variation Application, European Medicines Agency, Ema, Switch-1, Switch-2, Tresiba, Diabetes, Long-acting
